Ramiro M. Perrotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramiro M. Perrotta has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Gabriel A. Rabinovich
Programa de Glicoinmunología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 1428, Ciudad de Buenos Aires, Argentina
18 shared publicationsTomás Dalotto-Moreno
Programa de Glicoinmunología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 1428, Ciudad de Buenos Aires, Argentina
18 shared publicationsAna Sahores
17 shared publicationsCarol A. Sartorius
17 shared publications- Caroline A. Lamb
Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina
17 shared publications - Claudia Lanari
Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
17 shared publications
Latest Publications
- Open Access
A Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset
SUMMARY: Early dissemination of breast cancer cells can occur before clinically detectable tumor progression; yet the molecular programs enabling this process remain poorly defined. Here, we identify a conserved glycocheckpoint, mediated by the galectin-1 (GAL1)-glycan axis, that links normal mammary gland morphogenesis to early breast cancer dissemination and metastasis. During mammary gland development, regulated GAL1 expression and glycan accessibility directed epithelial lineage specification and progesterone-induced branching morphogenesis. This morphogenetic program was aberrantly reactivated in early breast cancer lesions and co-opted to promote tumor cell dissemination. Genetic ablation and pharmacological inhibition of GAL1 in mouse models (mammary tumor virus-polyoma middle T antigen (MMTV-PyMT and MMTV-HER2), together with patient-derived data, revealed that this lectin drives epithelial-to-mesenchymal transition, acquisition of stem-like traits, and metastatic competence in breast cancer. Therapeutic targeting of GAL1 reduced early lesions and their progression, decreased circulating tumor cell frequency, and limited lung metastasis in the MMTV-HER2 tumor model. Consistently, high transcriptomic levels of GAL1 together with low levels of the enzyme β-galactoside α2,6-sialyltransferase 1 ( ST6GAL1 ), that catalyzes α2,6-linked sialylation and limits GAL1 binding, was associated with poor clinical outcome in breast cancer patients. These findings reveal that early breast cancer dissemination hijacks a GAL1-glycan morphogenetic program, uncovering a direct link between mammary development and metastatic progression, highlighting GAL1 as a therapeutic vulnerability in early-stage disease.
Open AccessA Developmental Lectin-Glycan Program Enables Early Breast Cancer Dissemination and Metastatic Onset
SUMMARY: Early dissemination of breast cancer cells can occur before clinically detectable tumor progression; yet the molecular programs enabling this process remain poorly defined. Here, we identify a conserved glycocheckpoint, mediated by the galectin-1 (GAL1)-glycan axis, that links normal mammary gland morphogenesis to early breast cancer dissemination and metastasis. During mammary gland development, regulated GAL1 expression and glycan accessibility directed epithelial lineage specification and progesterone-induced branching morphogenesis. This morphogenetic program was aberrantly reactivated in early breast cancer lesions and co-opted to promote tumor cell dissemination. Genetic ablation and pharmacological inhibition of GAL1 in mouse models (mammary tumor virus-polyoma middle T antigen (MMTV-PyMT and MMTV-HER2), together with patient-derived data, revealed that this lectin drives epithelial-to-mesenchymal transition, acquisition of stem-like traits, and metastatic competence in breast cancer. Therapeutic targeting of GAL1 reduced early lesions and their progression, decreased circulating tumor cell frequency, and limited lung metastasis in the MMTV-HER2 tumor model. Consistently, high transcriptomic levels of GAL1 together with low levels of the enzyme β-galactoside α2,6-sialyltransferase 1 ( ST6GAL1 ), that catalyzes α2,6-linked sialylation and limits GAL1 binding, was associated with poor clinical outcome in breast cancer patients. These findings reveal that early breast cancer dissemination hijacks a GAL1-glycan morphogenetic program, uncovering a direct link between mammary development and metastatic progression, highlighting GAL1 as a therapeutic vulnerability in early-stage disease.
- Open Access
- 18 December 2025
- Published by Springer Nature in Nature Biotechnology
Engineered base editors with reduced bystander editing through directed evolution
Base editors enable precise genome modification but are constrained by bystander edits that limit their applicability. Existing strategies to enhance precision often compromise efficiency and remain highly sequence dependent. Here we present a parallel engineering approach that optimizes both guide RNAs and the deaminase enzyme to minimize bystander editing without sacrificing activity. We designed a library of 3'-extended guide RNAs and identified context-dependent variants that improved specificity. Using a precision-driven phage-assisted evolution system and protein language models, we evolved adenine base editor variants two- to threefold more precise than adenine base editor ABE8e while maintaining high efficiency across a library of thousands of human pathogenic contexts in vitro. Our findings establish a scalable framework for precision engineering of base editors, addressing a major challenge in genome editing.
- 18 December 2025
- Published by Springer Nature in Nature Biotechnology
Open AccessEngineered base editors with reduced bystander editing through directed evolution
Base editors enable precise genome modification but are constrained by bystander edits that limit their applicability. Existing strategies to enhance precision often compromise efficiency and remain highly sequence dependent. Here we present a parallel engineering approach that optimizes both guide RNAs and the deaminase enzyme to minimize bystander editing without sacrificing activity. We designed a library of 3'-extended guide RNAs and identified context-dependent variants that improved specificity. Using a precision-driven phage-assisted evolution system and protein language models, we evolved adenine base editor variants two- to threefold more precise than adenine base editor ABE8e while maintaining high efficiency across a library of thousands of human pathogenic contexts in vitro. Our findings establish a scalable framework for precision engineering of base editors, addressing a major challenge in genome editing.
- Open Access
Preventing escape and malfunction of recoded cells due to tRNA base changes
Engineering the genetic code restricts DNA transfer (cellular bioisolation) and enables new chemistries via non-standard amino acid incorporation. These distinct properties make recoded cells state-of-the-art safe technologies. However, evolutionary pressures may endanger the longevity of the recoding. Here, we reveal that recoded Escherichia coli lacking 18,214 serine codons and two tRNA Ser can express wild-type antibiotic resistance genes and escape up to seven orders of magnitude faster than expected. We show a two-step escape process whereby recoded cells mistranslate antibiotic resistance genes to survive until modified or mutated tRNAs reintroduce serine into unassigned codons. We developed genetic-code-sensitive kill switches that sense serine incorporation and prevent cellular escape while preserving encoding of three distinct non-standard amino acids. This work lays the foundation for the long-term controlled function of cells that incorporate new chemistries, with implications for the design, use, and biosafety of synthetic genomes in clinical and environmental applications where physical containment is insufficient.
Open AccessPreventing escape and malfunction of recoded cells due to tRNA base changes
Engineering the genetic code restricts DNA transfer (cellular bioisolation) and enables new chemistries via non-standard amino acid incorporation. These distinct properties make recoded cells state-of-the-art safe technologies. However, evolutionary pressures may endanger the longevity of the recoding. Here, we reveal that recoded Escherichia coli lacking 18,214 serine codons and two tRNA Ser can express wild-type antibiotic resistance genes and escape up to seven orders of magnitude faster than expected. We show a two-step escape process whereby recoded cells mistranslate antibiotic resistance genes to survive until modified or mutated tRNAs reintroduce serine into unassigned codons. We developed genetic-code-sensitive kill switches that sense serine incorporation and prevent cellular escape while preserving encoding of three distinct non-standard amino acids. This work lays the foundation for the long-term controlled function of cells that incorporate new chemistries, with implications for the design, use, and biosafety of synthetic genomes in clinical and environmental applications where physical containment is insufficient.
- Open Access
Machine Learning and Directed Evolution of Base Editing Enzymes
As we enter the era of CRISPR medicines, base editors (BEs) emerged as one of the most promising tools to treat genetic associated diseases. However, unintended bystander editing beyond the target nucleotide poses a challenge to their translation into effective therapies. While many efforts have been made in the design of a universal enzyme with minimal bystander editing, the context dependent activity represents a major challenge for base editing-based therapies. In this work, we designed a sequence-specific guide RNA library with 3’-extensions and detected guides that were able to reduce bystander and increase editing efficiency in a context dependent manner. The best candidate was later used for phage assisted non-continuous evolution to find a new generation of precise base editors. Simultaneously, we use protein language models trained on massive protein sequence datasets to find the evolutionarily plausible mutational patterns that can improve deaminase activity and precision. Both strategies provide a collection of precise TadA variants that not only drastically reduced bystander edits, but also was not in detriment of on-target activity. Our findings introduce a guide/enzyme parallel engineering pipeline, which lays the foundation for the development of new personalized genome editing strategies, ultimately enhancing the safety and precision of this groundbreaking technology.
Open AccessMachine Learning and Directed Evolution of Base Editing Enzymes
As we enter the era of CRISPR medicines, base editors (BEs) emerged as one of the most promising tools to treat genetic associated diseases. However, unintended bystander editing beyond the target nucleotide poses a challenge to their translation into effective therapies. While many efforts have been made in the design of a universal enzyme with minimal bystander editing, the context dependent activity represents a major challenge for base editing-based therapies. In this work, we designed a sequence-specific guide RNA library with 3’-extensions and detected guides that were able to reduce bystander and increase editing efficiency in a context dependent manner. The best candidate was later used for phage assisted non-continuous evolution to find a new generation of precise base editors. Simultaneously, we use protein language models trained on massive protein sequence datasets to find the evolutionarily plausible mutational patterns that can improve deaminase activity and precision. Both strategies provide a collection of precise TadA variants that not only drastically reduced bystander edits, but also was not in detriment of on-target activity. Our findings introduce a guide/enzyme parallel engineering pipeline, which lays the foundation for the development of new personalized genome editing strategies, ultimately enhancing the safety and precision of this groundbreaking technology.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
The role of active antitumor immunity in hormone receptor–positive (HR+) breast cancer has been historically underlooked. The aim of this study was to determine the contribution of the immune system to antiprogestin-induced tumor growth inhibition using a hormone-dependent breast cancer model. BALB/c-GFP+ bone marrow (BM) cells were transplanted into immunodeficient NSG mice to generate an immunocompetent NSG/BM-GFP+ (NSG-R) mouse model. Treatment with the antiprogestin mifepristone (MFP) inhibited growth of 59–2-HI tumors with similar kinetics in both animal models. Interestingly, MFP treatment reshaped the tumor microenvironment, enhancing the production of proinflammatory cytokines and chemokines. Tumors in MFP-treated immunocompetent mice showed increased infiltration of F4/80+ macrophages, natural killer, and CD8 T cells, displaying a central memory phenotype. Mechanistically, MFP induced immunogenic cell death (ICD) in vivo and in vitro, as depicted by the expression and subcellular localization of the alarmins calreticulin and HMGB-1 and the induction of an ICD gene program. Moreover, MFP-treated tumor cells efficiently activated immature dendritic cells, evidenced by enhanced expression of MHC-II and CD86, and induced a memory T-cell response, attenuating tumor onset and growth after re-challenge. Finally, MFP treatment increased the sensitivity of HR+ 59–2-HI tumor to PD-L1 blockade, suggesting that antiprogestins may improve immunotherapy response rates. These results contribute to a better understanding of the mechanisms underlying the antitumor effect of hormonal treatment and the rational design of therapeutic combinations based on endocrine and immunomodulatory agents in HR+ breast cancer.Significance:Antiprogestin therapy induces immunogenic tumor cell death in PRA-overexpressing tumors, eliciting an adaptive immune memory response that protects mice from future tumor recurrence and increases sensitivity to PD-L1 blockade.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
The role of active antitumor immunity in hormone receptor–positive (HR+) breast cancer has been historically underlooked. The aim of this study was to determine the contribution of the immune system to antiprogestin-induced tumor growth inhibition using a hormone-dependent breast cancer model. BALB/c-GFP+ bone marrow (BM) cells were transplanted into immunodeficient NSG mice to generate an immunocompetent NSG/BM-GFP+ (NSG-R) mouse model. Treatment with the antiprogestin mifepristone (MFP) inhibited growth of 59–2-HI tumors with similar kinetics in both animal models. Interestingly, MFP treatment reshaped the tumor microenvironment, enhancing the production of proinflammatory cytokines and chemokines. Tumors in MFP-treated immunocompetent mice showed increased infiltration of F4/80+ macrophages, natural killer, and CD8 T cells, displaying a central memory phenotype. Mechanistically, MFP induced immunogenic cell death (ICD) in vivo and in vitro, as depicted by the expression and subcellular localization of the alarmins calreticulin and HMGB-1 and the induction of an ICD gene program. Moreover, MFP-treated tumor cells efficiently activated immature dendritic cells, evidenced by enhanced expression of MHC-II and CD86, and induced a memory T-cell response, attenuating tumor onset and growth after re-challenge. Finally, MFP treatment increased the sensitivity of HR+ 59–2-HI tumor to PD-L1 blockade, suggesting that antiprogestins may improve immunotherapy response rates. These results contribute to a better understanding of the mechanisms underlying the antitumor effect of hormonal treatment and the rational design of therapeutic combinations based on endocrine and immunomodulatory agents in HR+ breast cancer.Significance:Antiprogestin therapy induces immunogenic tumor cell death in PRA-overexpressing tumors, eliciting an adaptive immune memory response that protects mice from future tumor recurrence and increases sensitivity to PD-L1 blockade.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 1: The NSG-R mouse model mimics an immunocompetent host.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 1: The NSG-R mouse model mimics an immunocompetent host.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 5: MFP treatment boosts antitumor T cell priming and activation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 5: MFP treatment boosts antitumor T cell priming and activation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 2. MFP induces tissue remodeling in tumors growing in NSG-R mice.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 2. MFP induces tissue remodeling in tumors growing in NSG-R mice.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 4. 59-2-HI tumors express PD-L1 and MFP treatment upregulates PD-L1 expression in CD45neg cells and F4/80+ macrophages in vivo
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Figure 4. 59-2-HI tumors express PD-L1 and MFP treatment upregulates PD-L1 expression in CD45neg cells and F4/80+ macrophages in vivo
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Materials and methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Supplementary Materials and methods